$7.460
-0.050 (-0.67%)收盤時
SENS 資訊
SENS 事件
Senseonics Initiates First-in-Human Clinical Study
Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter. The study's purpose is to demonstrate safety and generate insights to inform a planned pivotal study that Senseonics expects to initiate in 2027, with the company targeting a potential commercial launch in 2028.
Beta Bionics Partners with Senseonics for New System Launch
Beta Bionics (BBNX) announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics' (SENS) Eversense 365 continuous glucose monitoring system. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system.
Senseonics Partners with Beta Bionics to Develop Automated Insulin Delivery System
Senseonics (SENS) announced a partnership with Beta Bionics (BBNX). The companies are collaborating to integrate Eversense 365 CGM with Beta Bionics' iLet Bionic Pancreas automated insulin delivery system designed to simplify diabetes management.
Senseonics Reports Q2 Revenue of $14.5M, Exceeds Expectations
Reports Q2 revenue $14.5M, consensus $12.91M. U.S. revenue grew more than 150% year-over-year to $12.6M. "This was the strongest quarter in Senseonics' history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs," said CEO Tim Goodnow.
Company Raises FY26 Gross Margin Guidance to 58%-61%
Consensus $62.18M. Raises FY26 gross margin guidance to a range of 58%-61% from 55%-58%. "Given our momentum, we're raising our full-year revenue and margin guidance. We're not just growing the business - we're redefining what a CGM can be," said CEO Tim Goodnow.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。